Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,159 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Macular Degeneration, Age-related, Geographic Atrophy
Interventions: BI 771716, Pegcetacoplan, Sham comparator to BI 771716; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more

Conditions: Extraocular Retinoblastoma, Intraocular Retinoblastoma, Recurrent Retinoblastoma
Interventions: Laboratory Biomarker Analysis, Questionnaire Administration; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 49
States / cities: Los Angeles, California • Madera, California • San Francisco, California + 38 more

Conditions: Psoriasis, Obesity
Interventions: Ixekizumab, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more

Conditions: Carcinoma
Interventions: Everolimus, Everolimus Placebo, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more

Conditions: Liver Cancer
Interventions: radiofrequency ablation; Device
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 13 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Estradiol/Norethindrone Acetate, Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more

Conditions: Lung Cancer
Interventions: Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin; Radiation · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 930
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 575 more

Conditions: Colorectal Cancer
Interventions: romidepsin; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 88
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Adverse Events
Interventions: Irrisept, Standard of Care; Device
Lead sponsor: Irrimax Corporation; Industry
Eligibility: Not listed
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Breast Cancer
Interventions: Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 386
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more

Conditions: Liver Transplant
Interventions: OCS Liver; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 17
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 14 more

Conditions: Obesity
Interventions: Promotion of positive deviance behaviors, Promotion of healthy behaviors; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 5 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Congenital Heart Disease (CHD)
Interventions: Umbilical Cord Clamping at ~30 seconds, Umbilical Cord Clamping at ~120 seconds, Umbilical Cord Milking; Procedure
Lead sponsor: Carl Backes, MD; Other
Eligibility: 37 Weeks to 42 Weeks
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 15 more

Conditions: Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 2,545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 175
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more

Conditions: Pancreatic Cancer
Interventions: dipyridamole, fluorouracil, leucovorin calcium, mitomycin C; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 84
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Tachycardia, Ventricular, Heart Failure, Congestive, Ventricular Fibrillation, Ventricular Dysfunction, Bradycardia
Interventions: Not listed
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 3,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 113
States / cities: Tucson, Arizona • Little Rock, Arkansas • Fresno, California + 107 more

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin, glimepiride, linagliptin placebo, glimepiride placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 6,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 177
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more

Conditions: Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 2 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 129
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more

Conditions: Educational Problems, Orthopedic Disorder, Emergencies
Interventions: Education Curriculum; Other
Lead sponsor: Jared L. Cohen; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Optim Lead Insulation Related Adverse Events
Interventions: Not listed
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 14,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 245
States / cities: Alabaster, Alabama • Fort Payne, Alabama • Gadsden, Alabama + 189 more

Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Interventions: TVB-2640 25 mg (US), TVB-2640 50 mg (US), Placebo (US), TVB-2640 50 mg (China), Placebo (China), TVB-2640 75 mg (US); Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Chula Vista, California • Montclair, California • Sacramento, California + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
Interventions: ABBV-319; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more

Conditions: Insulin Stimulated
Interventions: Insulin 80mU/m2*min; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer

Retrospective Independent Safety Review of Closed Irrisept Study

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

OCS Liver PROTECT Continuation Post-Approval Study

Parent Mentors Using Positive Deviance in Childhood Obesity

Cord Clamping Among Neonates With Congenital Heart Disease

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Assessment of an Orthopedic Surgery Rotation on Musculoskeletal Competency in Emergency Medicine Residency Training

Lead Registry for Optim Leads

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Molecular Mechanisms of Type 2 Diabetes Mellitus

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Genetics of Skeletal Muscle Insulin Resistance